Professor DeLun Luo, President of Yunhai Bio, Invited to Attend the 2025 “Gusu Dialogue”

To promote the green transformation of the pharmaceutical industry and advance national strategies such as “high-quality development” and the “dual carbon goals,” the 2025 Gusu Dialogue was grandly held in Suzhou from August 26 to 28. Professor DeLun Luo, President of Yunhai Bio, was invited as a distinguished representative in the field to deliver a keynote report.

At the conference, Professor DeLun Luo gave a special presentation titled “Applications and Industrialization Progress of Tetrahedral Framework Nucleic Acids (tFNAs),” sharing cutting-edge research outcomes and translational progress. His report systematically elaborated on the mechanisms and application potential of tFNAs in ophthalmology, neurology, and medical aesthetics, while highlighting interim achievements from collaborations with clinical teams—drawing wide attention from attending experts.

As an innovative enterprise in China specializing in nucleic acid nanomaterials and delivery technologies, Yunhai Bio has already established pipelines in ophthalmology, neurology, and medical aesthetics. Looking ahead, the company will continue to work closely with industry and investment partners to accelerate the translation of scientific achievements, bringing patients safer and more accessible new treatment options.